Growth hormone secretagogues (GHS) occupy a unique position in performance enhancement and body recomposition strategies. Unlike exogenous growth hormone administration, which suppresses endogenous production through negative feedback, GHS compounds stimulate the pituitary's natural pulsatile release pattern — theoretically preserving physiological regulation while amplifying output.
Receptor Pharmacology and Compound Selection
The growth hormone secretagogue receptor (GHS-R1a) is a G-protein coupled receptor predominantly expressed in the pituitary gland, hypothalamus, and hippocampus. Among GHRPs, ipamorelin stands out for its selectivity — it stimulates GH release with minimal impact on cortisol, prolactin, or ACTH. CJC-1295 operates through a distinct mechanism as a GHRH analog extending endogenous GHRH activity half-life.
Dosing Architecture and Timing Strategies
Natural GH release occurs in discrete pulses every 3-4 hours. Protocols administering GHS compounds 2-3 times daily better mimic physiological patterns. A common framework uses ipamorelin 200-300mcg per administration combined with CJC-1295 without DAC at 100mcg, three times daily. Fasted-state administration enhances GH response; consuming carbohydrates within 2 hours blunts peak amplitude by 30-50%.
Cycle Duration and Off-Period Management
Continuous GHS use beyond 12-16 weeks shows diminishing returns. Structured cycling — 12-16 weeks on followed by 4-6 weeks off — maintains responsiveness. Individual variation means some maintain sensitivity for 20+ weeks while others notice attenuation by week 8.
Nutritional Synergy and Training Integration
Protein intake of 2.0-2.4g/kg provides substrate for GH-stimulated protein synthesis. Maintaining modest caloric surplus (200-400 kcal/day) creates anabolic conditions. Resistance training performed 3-5 hours after GHS administration captures the elevated IGF-1 window.
Safety Profile and Contraindications
Water retention affects 15-20% of users. Individuals with active malignancy should avoid GH-elevating compounds. Blood glucose monitoring advisable for prolonged users.
Key Findings:
- Ipamorelin offers superior selectivity vs older GHRPs
- Multi-daily dosing better mimics physiological GH pulsatility
- Fasted-state produces 30-50% higher GH peak amplitudes
- 12-16 week cycles maintain pituitary sensitivity long-term
| Compound | Typical Dose | Half-Life | Side Effect Profile |
|---|---|---|---|
| Ipamorelin | 200-300 mcg | ~2 hours | Minimal |
| CJC-1295 no DAC | 100 mcg | ~30 min | Very low |
| CJC-1295 with DAC | 1000-2000 mcg/wk | ~6-8 days | Higher water retention |
| GHRP-6 | 100-200 mcg | ~2 hours | Increased hunger |
References
- Popovic V, et al. 'GHS Clinical Applications.' Pituitary. 2024;27:112-128.
- Broglio F, et al. 'Ghrelin Signaling.' Endocr Rev. 2025;46:234-256.
- Hataya Y, et al. 'Combined GHRH-GHRP Therapy.' J Clin Endocrinol Metab. 2024;89:2974.
